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Abstract
Mitochondria contain a 16.6 kb circular genome encoding 13 proteins as well as mitochondrial tRNAs and rRNAs.
Copies of the genome are organized into nucleoids containing both DNA and proteins, including the machinery
required for mtDNA replication and transcription. The transcription factor TFAM is critical for initiation of transcription
and replication of the genome, and is also thought to perform a packaging function. Although specific binding sites
required for initiation of transcription have been identified in the D-loop, little is known about the characteristics of
TFAM binding in its nonspecific packaging state. In addition, it is unclear whether TFAM also plays a role in the
regulation of nuclear gene expression. Here we investigate these questions by using ChIP-seq to directly localize
TFAM binding to DNA in human cells. Our results demonstrate that TFAM uniformly coats the whole mitochondrial
genome, with no evidence of robust TFAM binding to the nuclear genome. Our study represents the first high-
resolution assessment of TFAM binding on a genome-wide scale in human cells.
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Introduction
Mitochondria are essential eukaryotic organelles, serving as
the epicenter of ATP production in the cell through oxidative
phosphorylation. To perform this bioenergetic function,
mitochondria utilize gene products encoded by the
mitochondrial genome, a circular DNA that is 16.6 kb long. This
genome is organized into DNA/protein structures termed
nucleoids [1]. Mitochondrial DNA (mtDNA) encodes thirteen
components of the electron transport chain, as well as 22
tRNAs and two ribosomal RNA genes. These gene products
are essential for the proper function of the respiratory chain,
and therefore maintenance of mtDNA levels and sequence
fidelity is essential for cellular bioenergetics. In a human cell,
there are hundreds to thousands of copies of the mtDNA
genome [2,3]. Damage or depletion of mtDNA causes
numerous inherited disorders, including Alpers’ Disease, ataxia
neuropathy spectrum, and progressive external
ophthalmoplegia [4,5]. Furthermore, loss and damage to
mtDNA has been implicated in cardiovascular disease [6–9],
diabetes [10–12], neurodegenerative disorders such as
Alzheimer’s [13,14], and aging [15,16]. Strikingly, increasing
mtDNA copy number promotes cell survival or function in many
models of disease associated with decreased mtDNA
abundance, such as diabetes [12,17], aging [18], Alzheimer’s
[19], and Parkinson’s [20,21]. Thus, it is critical to understand
how mtDNA copy number and integrity are maintained.
Mitochondrial transcription factor A (TFAM) is a DNA binding
protein that plays multiple roles in regulating mtDNA function.
As a sequence-specific transcription factor, it binds upstream of
the light strand promoter (LSP) and heavy strand promoter 1
(HSP1) to activate initiation of transcription. At these sites, the
footprint of TFAM binding is ~22 bp long [22,23]. As a result,
TFAM is essential for production of gene products from the
mitochondrial genome. In addition, TFAM is required for normal
mtDNA copy number, because RNA primers generated from
LSP are used to prime mtDNA replication [24,25]. Mice
heterozygous for a knockout of TFAM exhibit not only an
expected reduction (22%) in mitochondrial transcript levels in
the heart and kidney, but also a universal 34% reduction in
mtDNA copy number across all assayed tissues. Furthermore,
homozygous knockout mice have no detectable levels of
mtDNA and die during embryogenesis [26], highlighting the
importance of TFAM in maintenance of mtDNA levels and in
cellular and organismal viability.
Apart from its sequence-specific functions, TFAM is thought
to organize the mtDNA genome by coating it in a nonspecific
manner. Although how TFAM packages mtDNA is not well-
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understood, it is known to bind nonspecifically to DNA [27] and
is estimated to be sufficiently abundant to coat the genome
completely [28–30]. One model suggests that nonspecific
binding radiates from the TFAM LSP binding site, which acts as
a nucleation site for subsequent cooperative binding in a
phased pattern to yield an inter-genome homogeneous pattern
of binding [31,32]. The packaging function of TFAM appears to
have important consequences for maintenance of the mtDNA
genome. A TFAM variant that is deficient in transcriptional
activation but competent in DNA binding is capable of
preventing mtDNA depletion [33]. Therefore, as a prominent
component of mtDNA nucleoids, TFAM appears to coat the
mitochondrial genome, perhaps protecting it from turnover or
deleterious damage.
Despite the importance of the associations of TFAM with
mtDNA in the maintenance of mtDNA integrity and in cellular
viability, these interactions have only been visualized in vivo at
low resolution [34]. Therefore, to capture a high-resolution
profile of TFAM-mtDNA interactions across the entire
mitochondrial genome, we performed chromatin
immunoprecipitation followed by massively parallel sequencing
(ChIP-seq) for TFAM in human HeLa cells.
Results
Detection of TFAM-DNA interactions using ChIP-seq
To characterize TFAM binding to both the mitochondrial and
nuclear genomes in an unbiased manner, we performed ChIP-
seq targeting TFAM in HeLa cells. Because ChIP-seq data is
highly dependent on the use of high-quality antibodies, we
generated two new TFAM monoclonal antibodies (20G2C12
and 20F8A9) that efficiently immunoprecipitated TFAM (Figure
1A). Both of these antibodies gave clean mitochondrial and
nucleoid signals in immunofluorescence experiments with
cultured HeLa cells (Figure 1C,D). The 20G2C12 antibody also
performed well in Western blots of whole-cell lysates,
recognizing a single protein band of ~23 kDa (Figure 1B).
Given the high efficiency of 20G2C12 in immunoprecipitating
TFAM, as well as its high specificity, we used it to capture
TFAM-associated DNA fragments for ChIP-seq analysis. DNA
was sonicated prior to immunoenrichment and size-selected
prior to library building so that the average fragment length of
the final library was centered around 200 bp, a fragment
distribution allowing for high-resolution deconvolution of binding
events. We generated 3 replicates and matching controls. The
sequencing depth of all samples was between 18 million and
48 million mappable reads, which is generally sufficient for
comprehensive identification of transcription factor binding sites
[35].
A common concern with ChIP-seq datasets is the variability
of enrichment for true binding events as compared to
background. In a typical ChIP-seq experiment, a minority of
sequencing reads originates from binding events, with the
majority representing random genomic DNA. Even for the
same DNA binding factor, large variations in the strength of
enrichment can be observed, and therefore it is critical to
assess the degree of enrichment before downstream analysis.
A number of ChIP-seq quality control metrics have been
developed [35] for nuclear transcription factors. However,
TFAM is expected to bind to the mitochondrial genome, which
has very different characteristics from the nuclear genome. In
addition, it is predicted to bind both in the classical localized
manner [36] as well as broadly across the mitochondrial
genome. As a result, metrics for evaluating nuclear
transcription factors are not well-suited for analysis of TFAM
binding data. We therefore examined the fraction of
sequencing reads in our libraries mapping to the mitochondria
as a proxy for the enrichment of TFAM binding events.
Strikingly, between 30% and 75% of TFAM ChIP-seq reads
mapped to the mitochondrial genome, while less than 2% of
reads mapped to the mitochondrial genome in the input
samples, indicating that our TFAM ChIP-seq datasets are
indeed highly enriched for TFAM binding events (Figure 1B).
We note that 75% ChIP enrichment is extremely high (in fact,
practically unprecedented) for any transcription factor dataset
[35], thus underscoring the high experimental quality of our
datasets.
Because partial copies of the mitochondrial genome are also
present in the nuclear genome, not all reads originating from
mtDNA can be mapped uniquely. Therefore, we characterized
TFAM binding to mtDNA and to the nuclear genome
separately. We analyzed mitochondrial binding events by
aligning sequencing reads to the mitochondrial genome alone
(restricting our analysis to reads mapping perfectly without any
mismatches to further increase mapping accuracy), and
analyzed binding to the nuclear genome by aligning only the
reads which did not map to the mitochondrial genome, as
outlined in Figure 2A. For a standard nuclear transcription
factor, this approach may cause some reads originating from
the nuclear genome to artificially map to the mitochondrial
genome. However, given that TFAM is known to bind to the
mitochondrial genome and the extremely high enrichment for
TFAM binding to mtDNA in our TFAM ChIP-seq libraries, this
should not be a significant confounding factor.
TFAM coats the mitochondrial genome
As discussed above, TFAM has not only been proposed to
bind specifically to well-defined binding sites in the D-loop, but
has also been suggested to play a nonspecific packaging role
in the nucleoid that is essential for mtDNA integrity. However,
little is known about the pattern of non-specific binding of
TFAM to the mitochondrial genome. Localized binding at the D-
loop and diffuse binding across the rest of the genome are
expected to result in distinct ChIP-seq signal profiles.
Localized, “point-source” binding to DNA results in an
asymmetric distribution of reads mapping to the forward and
reverse strand around the binding site of the protein [36,37],
while diffuse binding does not produce such strand asymmetry.
To characterize TFAM binding to mtDNA, we examined the
forward and reverse strand read distribution after mapping
TFAM ChIP-seq and input library reads to the mitochondrial
genome. Strikingly, we did not observe regions of obvious
enrichment and strand asymmetry in the D-loop; in particular,
we did not see specific binding at the predicted HSP1 and LSP
sites. On the whole, the TFAM ChIP-seq signal was broadly
distributed over the whole mitochondrial chromosome, and
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Figure 1.  Characterization of TFAM monoclonal antibodies.  (A) Immunoprecipitation of TFAM from cell lysates. HeLa cell
lysate was applied to sheep anti-mouse Dynabeads conjugated to anti-Myc, 20G2C12 TFAM antibody, 20F8A9 TFAM antibody, or
a 50/50 mixture of 20G2C12 and 20F8A9 TFAM antibodies. The labeled bands are: 1) Antibody heavy chain; 2) antibody light chain;
3) TFAM. (B) Western blot using the 20G2C12 antibody detects a ~23kDa band. (C and D) Immunocytochemistry showing TFAM
localization. Mitochondria were identified by PPIF staining; mtDNA was identified by anti-DNA staining. There was no evidence for
nuclear localization of TFAM using either antibody.
doi: 10.1371/journal.pone.0074513.g001
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while coverage was not perfectly uniform, the amplitude of the
non-uniformity was not significant, and the signal profile closely
tracked that of the input sample (Figure 3). The low level of
non-uniformity likely results from sequencing biases, which has
been documented to skew coverage [38,39]. Because our
libraries were carefully size-selected for fragments in the 200
bp range, discrete TFAM binding sites would be expected to
yield discrete signal localizations. Therefore, we interpret these
results as evidence for the uniform coating of the whole
mitochondrial genome by TFAM. We observed one region of
apparent localized enrichment exhibiting strand asymmetry in
the ND2 ORF near the origin of light strand replication (OL)
(Figure 3F), which we discuss in the Discussion section.
To further verify our results, we carried out ChIP-seq against
TFAM with a second TFAM monoclonal antibody, 20F8A9. We
obtained similar results (Figure S1) and found significant
Figure 2.  ChIP-seq analysis of genome-wide TFAM binding.  (A) Overview of computational processing of data. Reads were
trimmed to 36 bp and then either mapped against the mitochondrial genome (ChrM), or the complete hg19 version of the genome.
After removing multireads and alignments to the mitochondrial genome, peaks in the nuclear genome were called using MACS2. (B)
The proportion of sequencing reads mapping to chrM in ChIP and input datasets. All replicates of the ChIP-seq resulted in at least
30% of reads mapping to the mitochondrial genome, much greater than the 0.4-1.9% of reads mapping to mtDNA in the input
datasets. Replicates 1-3 were performed using the 20G2C12 antibody, while Replicate 4 was performed using the 20F8A9 antibody.
doi: 10.1371/journal.pone.0074513.g002
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Figure 3.  Coating of the mitochondrial genome by TFAM in HeLa cells.  Circos plot of plus strand and minus strand TFAM
ChIP-seq and input read density signal over chrM. (A, E) Annotation of protein coding (green on forward/heavy strand, red on
reverse/light strand), ribosomal RNA (blue) and tRNA (blue on forward/heavy strand, grey on reverse/light strand) transcripts. (B) D-
loop (black), LSP promoter (large red tile), known LSP TFAM binding site (small red tile), HSP promoter (large blue tile), known
HSP1 TFAM binding site (small blue tile), and origins of heavy strand replication (Ori-b, orange tile; OH, yellow tile). (C) TFAM ChIP-
seq signal on forward (red) and reverse (blue) strands. (D) Input signal on forward (red) and reverse (blue) strands. (F) Origin of
light strand replication (yellow tile). Note that the input signal is exaggerated 60-fold relative to the ChIP-seq signal in order to
visualize coverage irregularities. The signal from the TFAM ChIP-seq largely follows that of the input, indicating generalized binding
across the mitochondrial genome.
doi: 10.1371/journal.pone.0074513.g003
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correlation between the 20F8A9 dataset and the three datasets
obtained from the 20G2C12 antibody datasets (p < 0.0001).
No evidence for binding to the nuclear genome
Previous studies have suggested that TFAM can be found in
the nucleus and that it modulates the transcription of nuclear
genes. In rat neonatal cardiac myocytes, TFAM was found to
bind to the promoter of SERCA2, the homolog of human
sarco(endo) plasmic reticulum calcium-ATPase 2 (ATP2A2),
and was implicated in regulating its transcription [40]. Given the
extremely high degree of TFAM binding enrichment in our
datasets, any robust nuclear TFAM binding events should be
readily detectable. To analyze nuclear binding, we excluded all
sequencing reads mapping to the mitochondrial genome and
used the resulting set of reads to identify putative TFAM
binding sites. We first looked for significant global read
clustering using cross-correlation between reads mapping to
the forward and the reverse DNA strands [35,36]. Cross-
correlation plots for input samples and for TFAM ChIP-seq
datasets were indistinguishable from each other (Figure 4A,B).
Next, we called putative TFAM binding sites using MACS2 [41].
Using default settings (corresponding to a q-value cut-off of
10-2), we identified 72, 137 and 153 sites respectively for the
three replicates generated with antibody 20G2C12, and a
single site for the 20F8A9 antibody. However, manual
inspection of each of the identified sites revealed that all were
likely to represent artifacts, mostly associated with repetitive
DNA sequences, as none had the expected strand asymmetry
of read distribution around a binding site. Instead, the two
strand profiles at each site were identical (summarized in
Figure 4D, with the classic nuclear transcription factor NRSF
shown for comparison in Figure 4C), and numerous
unmappable regions and repetitive elements were present in
the immediate vicinity of many of the called sites. Inspection of
the ATP2A2 gene revealed no TFAM enrichment neither in the
promoter region nor anywhere else in the neighborhood of the
gene (Figure 4E). Furthermore, we do not detect nuclear
localization of TFAM in our cells (Figure 1C). Therefore, in
HeLa cells under normal growth conditions, we find no
evidence for specific binding of TFAM to nuclear target genes.
Discussion
Previous in vitro studies have suggested that TFAM binds
specifically to LSP and HSP1, and that it may also bind
nonspecifically in a phased manner. Furthermore, evidence
has been presented for its nuclear localization and action as a
canonical nuclear transcription factor in rat neonatal cardiac
myocytes. However, no direct genome-wide measurements of
TFAM binding have been previously reported. Our TFAM ChIP-
seq data reveal very high enrichment for reads mapping to the
mitochondrial genome, but a binding pattern that largely mirrors
the read distribution observed in the input DNA, suggesting
broad, non-specific binding to mitochondrial genome. This
pattern is highly reproducible, indicating that the average
population-wide state of TFAM-mtDNA interactions is stable.
We found no correlation between irregularities in TFAM signal
distribution and characteristics of the mitochondrial genome
such as GC content (data not shown). Thus, we conclude that
TFAM binds to the mitochondrial genome nonspecifically and
without bias when cells are grown under typical culture
conditions. Although we do not observe the synchronized
phased binding seen in in vitro studies, we cannot rule out a
model where individual mtDNAs have such a pattern of binding
initiating from a non-universal nucleation site.
Strikingly, we did not observe localized enrichment of binding
at the known LSP and HSP1 TFAM binding sites. Peak
patterns mirrored that of the input in these regions, and no
ChIP-seq peaks displaying the canonical strand asymmetry in
read distribution were observed. This finding can be explained
by a model in which the interaction of TFAM with the LSP and
HSP1 binding sites is relatively transient and infrequent
compared to a more stable non-specific association with the
genome in its packaging state.
We did detect one site in the genome exhibiting the
characteristics of a specific, localized ChIP-seq peak, centered
at 5175 bp in the ND2 ORF. The localized nature of the ChIP
signal at this site suggests higher occupancy of TFAM. This
peak localizes to 546 bp upstream of the OL. Strikingly, TFAM
has previously been localized 520 bp upstream of the OL of rat
mtDNA [42–44]. We found no sequence similarity between the
rat and human sites, and in general this region of the mtDNA
genome shows low homology between the two species.
Further work will be required to understand the significance of
this putative TFAM binding site.
Finally, analysis of all datasets for TFAM binding to the
nuclear genome yielded no hits distinguishable from common
ChIP-seq artifacts. Although Watanabe et al. observed
regulation of the SERCA2 gene in rat myocytes, we did not
detect TFAM binding at the promoter of its ortholog in humans.
Previous studies have shown nuclear localization of TFAM in
rat hepatoma cells [45], as well as an alternate isoform of
TFAM in mouse testis nuclei [46]. We have thus far been
unable to detect nuclear TFAM localization in HeLa cells
(Figure 1C), suggesting that nuclear localization and
transcriptional regulation may be cell type or perhaps species-
dependent. ChIP-seq in different cell lines may be able to
detect such nuclear interactions.
We demonstrate here the first high-resolution ChIP-seq
analysis of TFAM binding to the mitochondrial genome. Aside
from generalized, largely non-specific binding across the
mitochondrial genome, we detected a putative specific binding
site upstream of the origin of light strand replication. We do not
observe the expected binding at the known HSP1 and LSP
sites, nor did we identify any nuclear binding sites. An area that
remains to be explored is the dynamic nature of TFAM-DNA
interactions with respect to both the nuclear and mitochondrial
genomes. ChIP-chip on the yeast mitochondrial genome has
shown that metabolic changes can lead to differential binding
of the yeast TFAM homolog, Abf2p [47]. It is possible that such
remodeling also occurs in the mammalian system, and further
studies will provide insight into the dynamic nature of the
mtDNA-protein interactions within the nucleoid that serve to
protect its integrity.
TFAM Coating of the Mitochondrial Genome
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Figure 4.  Absence of TFAM binding to the nuclear genome.  (A) Cross-correlation plot of input DNA computed over the nuclear
genome. (B) Cross-correlation plot of TFAM ChIP-seq computed over the nuclear genome. (C) Distribution of ChIP-seq reads
mapping to the plus and minus strand around called binding sites in a ChIP-seq dataset for the NRSF transcription factor [51] in
HeLa cells, generated by the ENCODE consortium [52]. (D) Distribution of TFAM ChIP-seq reads mapping to the plus and minus
strand around called binding sites indicates lack of real binding sites. (E) No ChIP-seq enrichment around the promoter of the
SERCA2/ATP2A2 gene, previously suggested to be a TFAM target.
doi: 10.1371/journal.pone.0074513.g004
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Materials and Methods
Cell growth and treatment
HeLaS3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen #11995) containing 10% bovine
serum (Invitrogen #16170), penicillin and streptomycin, and
additional L-glutamine (2mM). Cells were fed 24 hours before
harvest for ChIP-seq, which was performed at 80-90%
confluency.
Antibody Production and characterization
Antibodies were produced by the Caltech Monoclonal
Antibody Facility and raised against the full-length TFAM
protein in mouse. Immunoprecipitation with 20G2C12 and
20F8A9 TFAM antibodies and Myc antibody (Santa Cruz
#sc-40) was performed according to established protocols
using M-280 sheep anti-mouse Dynabeads (Invitrogen
#11201D). Immunoblotting of IP products was performed using
a monoclonal TFAM 18G102B2E11 antibody, also custom
generated, at 1:2000, with goat anti-mouse HRP antibody
(1:10,000, Jackson ImmunoResearch #115-056-003).
Immunoblotting of HeLa whole cell lysate with 20G2C12 was
performed at a 1:200 dilution and with goat anti-mouse HRP
antibody.
Immunocytochemistry
HeLa cells cultured as described above were plated onto
poly-lysine coated glass coverslips 48 hours prior to fixation in
formaldehyde and permeabilization with 0.1% Triton X-100. For
colocalization of TFAM to mitochondria, 20G2C12 or 20F8A9
antibodies were used at 1:10 in conjunction with PPIF at 1:200
(ProteinTech #18466-1-AP). Secondary antibodies were goat
anti-mouse AF488 (1:500, Invitrogen #A11001) and donkey
anti-rabbit AF546 (1:500, Invitrogen #A10040). Cells were also
stained with DAPI to visualize nuclei. Immunocytochemistry to
visualize colocalization of mitochondrial nucleoids and TFAM
was performed sequentially due to both antibodies being raised
in mouse. Sequential immunostaining yielded no background
fluorescence due to cross-antibody reactivity (data not shown).
Order was as follows: anti-TFAM antibody (1:10); goat anti-
mouse AF488 (1:500, Invitrogen #A11001); anti-DNA antibody
(1:25, Millipore #CBL186); goat anti-mouse AF555 (1:500,
Invitrogen #A21426), DAPI. Images were acquired with a Zeiss
LSM 710 confocal microscope with PlanApochromat 63X/1.4
oil objective. Z-stack acquisitions were converted to maximum
z-projections using ImageJ software.
Chromatin immunoprecipitation and sequencing
ChIP experiments and preparation of DNA for sequencing
were performed following standard procedures [48] with some
modifications. Cells were fixed for 10min at RT in 1%
formaldehyde, harvested using a cell scraper, washed once in
ice-cold PBS, and resuspended in RIPA buffer with protease
inhibitor. The sample was then sonicated using a 3.2mm
microtip (QSonica Sonicator 4000) at 30s on/30s off intervals
and 40% amplitude for 180min while in a -30°C 3:1 isopropanol
and water bath containing dry ice. Subsequent steps were
performed as per the standard protocol. DNA was size-
selected during library building to an average fragment size of
200bp. Libraries were sequenced using Illumina GAIIx and
Illumina HiSeq 2000. Sequencing data is available under GEO
accession record GSE48176.
Sequencing data processing and analysis
Sequencing reads were trimmed down to 36 bp and then
mapped against either the female set of human chromosomes
(excluding the Y chromosome and all random chromosomes
and haplotypes) or the mitochondrial genome alone, using the
hg19 version of the human genome as a reference. Bow tie
0.12.7 [49] was used for aligning reads, not allowing for any
mismatches between the reads and the reference. ChIP-seq
peaks were called using MACS2 [41] with default settings
except for the mfold parameter, which was lowered to (2,30).
Circos plots were generated using Circos version 0.60 [50].
Additional data processing was carried out using custom-
written python scripts. ENCODE data was downloaded from
the UCSC browser (http://hgdownload-test.cse.ucsc.edu/
goldenPath/hg19/encodeDCC/wgEncodeHaibTfbs) and its use
here complies with its terms of usage. Pearson correlation
coefficient, t-test, and p values were calculated using
embedded and custom Microsoft Excel functions.
Supporting Information
Figure S1.  Comparison of profiles of TFAM binding to
mitochondrial genome.
Circos plots of TFAM ChIP-seq experiments: (1) 20F8A9
antibody ChIP-Seq; (2) 20G2C12 replicate 1; (3) 20G2C12
replicate 2; (4) 20G2C12 replicate 3. Read profiles are very
similar across replicates and antibodies.
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